Metabolism and efficacy study of ~(125)I-anti-AFP administrated by interventional route for primary liver cancer
- VernacularTitle:~(125)I-抗AFP抗体介入导向治疗肝癌的药物体内代谢和疗效观察
- Author:
Kehe CHEN
;
Yingde WU
;
Zhihui LIU
- Publication Type:Journal Article
- Keywords:
liver tumour;
pharmacokinetic;
transcatheter arterial chemoembolization;
targeting therapy
- From:
China Oncology
2000;0(06):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To study the characteristics of biological distribution in vivo and therapeutic efficacy of 125 I-anti-alpha-fetoprotein(AFP) antibody when administrated by the hepatic artery , and discussion of multi-modal therapy by transcatheter arterial chemoembolization(TACE) and immunization therapy. Methods:21 patients with moderately and advanced primary liver cancer (PLC) were treated by 125 I-anti -alpha-fetoprotein which was administered via hepatic artery, together with TACE and CD3AK cell by intravenous infusion to,detect the pharmacokinetic parameters and metabolism for 125 I-anti-AFP in vivo, and observe the efficacy of multi-modal treatment. Results:The radioactivity half-life time of ?phase (T 1/2 ?) and ? phase ( T 1/2 ?) for 125 I-anti-AFP antibodies was 1.85?1.79 and 156.46?65 hr,respectively; half-excretion time from urine was 94 hr, radiation intensity measured at body surface of organ suggested that the accumulated radioactivity was stronger and longer in the liver was than other organ.TPECT for tumour:liver ratio was 2.1?0.6. The efficacy for the treated group and the control group was respectively 61.9%(13/21) and 25.0%(5/20),the one-year cumulative survival rate of the treated group and the control group was also 61.9% and 25.0%.Conclusions: 125 I-anti-AFP via hepatic artery was able to concentrate electively in the tumour ,thereby bringing about a continuous internal irradiation for the tumour.This combined treatment is an effective method for PLC.
